$MFA

MFA: Keefe, Bruyette & Woods Raises Price Target to $11.00 on Market Perform Rating | MFA Stock News

Keefe, Bruyette & Woods analyst Bose George has increased the price target for MFA Financial (MFA) from $10.00 to $11.00, while maintaining a "Market Perform" rating. This adjustment comes amidst a series of diverse analyst ratings over recent months for the specialty finance company, which invests in residential mortgage assets. The average target price from four analysts is $10.69, suggesting a 6.34% upside from MFA's current price of $10.05.

Original reporting
GuruFocus · GuruFocus News
Published Feb 20, 2026, 2:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Feb 20, 2026, 3:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$MFA
Neutral
medium confidence
Mentioned
$MFA
Relevance
6/10
AlphAI data visualization · based on GuruFocus
Decision brief

The 30-second read

$MFANeutralMed
01

Why it matters

The analyst upgrade signals confidence but does not alter the company's fundamental valuation significantly.

02

Market read

The news is relevant for investors and traders focused on mortgage REITs and financial sector stocks, with moderate impact expected.

03

What to watch

Potential macroeconomic headwinds or changes in interest rates could negatively impact mortgage assets, offsetting analyst optimism.

Relevance 6/10Timing: short-term (next 1-3 weeks)

Background

MFA Financial is a mortgage REIT investing in residential mortgage assets, sensitive to interest rate changes and housing market trends.

Company-level read

Ticker impact

$MFANeutralMedium confidence
Context

The news pertains directly to MFA Financial, a company involved in residential mortgage assets, and includes a positive analyst rating adjustment.

Expected impact

Potential slight upward movement (~5%) in the short term, contingent on broader market conditions.

Evidence & confidence

The upgrade indicates positive analyst sentiment, but the 'Market Perform' rating and modest target suggest limited upside, making significant gains less likely without broader market support.

Market effects

The financial sector, particularly mortgage REITs and specialty finance companies, may experience slight positive sentiment.

Limited regional impact; primarily affects US mortgage finance sector.

Low; the news is specific to a US-based financial company.

Counterpoint

The rating upgrade may already be priced in; the company’s fundamentals or broader market conditions could limit upside.

Key entities

  • MFA Financial

    A mortgage real estate investment trust focusing on residential mortgage assets.

  • Keefe, Bruyette & Woods

    A financial services firm providing equity research and investment banking.

Related articles

$MFAMed

MFA Financial (MFA) Q2 2026 Earnings Call Transcript

MFA Financial (MFA) reported Q2 2026 results on an earnings call. Investment portfolio rose to $13.0B from $12.5B as Agency MBS grew. GAAP net income was $46.8M ($0.35/share). Distributable earnings were $12.2M ($0.12/share) after $24.5M realized credit losses. 60+ delinquency fell to 7.0% after ~$200M delinquent loan resolutions; G&A run rate guidance was $26M-$27M/quarter.

$MFAMed

MFA Financial, Inc. Announces Second Quarter 2026 Financial Results

MFA FINANCIAL, INC. (MFA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MFA FINANCIAL, INC. PRESS RELEASE FOR IMMEDIATE RELEASE August 5, 2026 NEW YORK METRO INVESTOR CONTACT: InvestorRelations@mfafinancial.com NYSE: MFA 212-207-6488 www.mfafinancial.com MEDIA CONTACT: H/Advisors Abernathy Sydney Isaacs 713-343-0427 MFA Financial, Inc. A

$MFAMed

BTIG Upgrades MFA Financial (MFA), Expects Dividend Coverage to Improve

BTIG upgraded MFA Financial (NYSE:MFA) to Buy from Neutral on June 17, setting a $10.50 price target. BTIG expects improved dividend coverage as realized losses from MFA’s legacy portfolio ease in the second half of the year, supporting distributable earnings and narrowing the stock’s valuation discount. RBC on June 3 cut its target to $10 and flagged near-term credit-loss pressure.

$BHVNMedAI 8/10

Biohaven partners with Ono in $100m IgG degrader deal

Biohaven has partnered with Ono Pharmaceutical in a $100m deal for its MoDE IgG degrader portfolio, including BHV-1300, BHV-1310, and BHV-1320. Ono gains exclusive rights in ASEAN, Taiwan, South Korea, and Japan, with an $80m upfront payment and a $20m milestone. Biohaven retains global rights and is eligible for 20% royalties. BHV-1300 is in Phase III trials for Graves' disease, showing up to 87% IgG reduction. According to Biohaven, Ono will help bring the technology to Asian markets.